Overview

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Status:
Completed
Trial end date:
2020-03-06
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
Phase:
Phase 3
Details
Lead Sponsor:
Cara Therapeutics, Inc.